Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Castle Biosciences Inc. CSTL

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:CSTL)

Fundamentals Snapshot (NDAQ:CSTL)

Current News (NDAQ:CSTL)

Castle Biosciences Reports Second Quarter 2022 Results

Business Wire 8 days ago

American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett's Esophagus

Business Wire 12 days ago

Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference

Business Wire 13 days ago

Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8

Business Wire July 25, 2022

DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma

Business Wire July 25, 2022

Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma

Business Wire July 20, 2022

Castle Biosciences Honored with a 2022 Arizona Top Workplace Award

Business Wire July 18, 2022

Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation's CURE OM Initiative

Business Wire June 23, 2022

Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022

Business Wire June 22, 2022

Opinion & Analysis (NDAQ:CSTL)

Castle Biosciences Shares Storm Higher After Quadrupling Q3 YoY Revenue

Streetwise Reports November 13, 2019

Bullboard Posts (NDAQ:CSTL)